文献速递血液净化与透析

选择性5-羟色胺再摄取抑制剂使用与血液透析患者髋部骨折风险

Selective Serotonin Reuptake Inhibitor Use and Hip Fracture Risk Among Patients on Hemodialysis.
PubMed 文献 · Am J Kidney Dis · 2019-10-09

本研究基于美国肾脏数据系统开展病例对照研究,纳入4912例髋部骨折病例和49120例对照,发现血液透析患者使用选择性5-羟色胺再摄取抑制剂(SSRI)与髋部骨折风险升高相关(调整OR 1.25,95%CI 1.17-1.35),新近短期使用关联更强(调整OR 1.43,95%CI 1.23-1.67)。

要点

  • 血液透析患者使用SSRI与髋部骨折风险增加相关。
  • 新近短期SSRI使用与髋部骨折的关联更强,提示可能涉及跌倒等急性机制。
  • 该研究未纳入矿物质骨代谢异常生物标志物,存在残余混杂可能。

核心结论

  • 血液透析患者使用SSRI与髋部骨折风险升高相关,长期和新近短期使用均存在关联。

研究设计与样本

  • 病例对照研究,利用美国肾脏数据系统识别2009年1月1日至2015年9月30日期间维持性血液透析患者中的髋部骨折病例,每个病例按索引日期匹配10个对照,最终纳入4912例病例和49120例对照。

主要发现

  • SSRI使用与髋部骨折风险增加相关,调整OR为1.25(95%CI 1.17-1.35)。
  • 任何、低、中、高SSRI使用的调整条件OR分别为1.25(95%CI 1.17-1.35)、1.20(95%CI 1.08-1.32)、1.31(95%CI 1.18-1.43)和1.26(95%CI 1.12-1.41)。
  • 新近短期SSRI使用与髋部骨折的关联调整OR为1.43(95%CI 1.23-1.67)。

临床怎么用

  • 在血液透析患者中处方SSRI时应评估髋部骨折风险,尤其是新近短期使用时。

局限性

  • 分析未捕获和校正矿物质骨代谢异常的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Use of selective serotonin reuptake inhibitors (SSRIs) has been associated with hip fracture risk in the general population. This study examined this relationship among patients with kidney failure treated by hemodialysis, a unique high-risk subpopulation, within which the impact of SSRIs on hip fracture risk remains unexplored. STUDY DESIGN: Case-control study. SETTINGS & PARTICIPANTS: Eligible cases of hip fracture among maintenance hemodialysis patients between January 1, 2009, and September 30, 2015, were identified using the US Renal Data System. Each case was matched on index date with 10 eligible controls. To be eligible, study participants needed to have more than 1 year of Medicare Parts A and B coverage and more than 3 years of Part D coverage. For a separate examination of new short-term SSRI exposure, we selected cases and controls with more than 18 months of Part D coverage and no prior antidepressant use for 1 year. EXPOSURE: During the 3-year Part D coverage period, use of SSRIs characterized as any (≥1 prescription filled), low, moderate, and high use (<20%, 20%-<80%, and≥80% of days covered by filled prescriptions, respectively). OUTCOME: We selected cases using International Classification of Diseases, Ninth Revision codes 820.xx and 821.xx. In addition to 1 of these codes tied to a hospitalization, we required a corresponding surgical procedural code within 7 days of diagnosis. ANALYTIC APPROACH: Conditional logistic regression to estimate unadjusted and multivariable-adjusted ORs and 95% CIs. RESULTS: We identified 4,912 cases and 49,120 controls. SSRI use was associated with increased hip fracture risk (adjusted OR, 1.25; 95% CI, 1.17-1.35). Risk for fracture was estimated for any, low, moderate, and high SSRI use: adjusted conditional ORs were 1.25 (95% CI, 1.17-1.35), 1.20 (95% CI, 1.08-1.32), 1.31 (95% CI, 1.18-1.43), and 1.26 (95% CI, 1.12-1.41), respectively. The association between hip fracture events and SSRI use was also seen in the examination of new short-term use (adjusted OR, 1.43; 95% CI, 1.23-1.67). LIMITATIONS: Biomarkers of mineral bone disorder were not captured and accounted for in this analysis. CONCLUSIONS: We demonstrated an association between increased hip fracture risk and both long- and new short-term SSRI use. The stronger association with new short-term use may suggest an acute mechanism potentially related to falls.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Vangala C, Niu J, Montez-Rath ME, et al. Selective Serotonin Reuptake Inhibitor Use and Hip Fracture Risk Among Patients on Hemodialysis. Am J Kidney Dis. 2019. PMID: 31606233. doi:10.1053/j.ajkd.2019.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。